Processa Pharmaceuticals, Inc. (PCSA) Net income 2016–2025
Processa Pharmaceuticals, Inc. (PCSA) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$13.6MFY2025 · since FY2016: -$1.9M → -$13.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$13.6M | -14.5% |
| FY2024 | -$11.9M | -6.6% |
| FY2023 | -$11.1M | +59.4% |
| FY2022 | -$27.4M | -140.0% |
| FY2021 | -$11.4M | +20.7% |
| FY2020 | -$14.4M | -329.3% |
| FY2019 | -$3.4M | +10.8% |
| FY2018 | -$3.8M | -102.8% |
| FY2017 | -$1.9M | +3.2% |
| FY2016 | -$1.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PCSA financial trends
PCSA RevenuePCSA Net marginPCSA Gross profitPCSA Gross marginPCSA Operating incomePCSA Operating marginPCSA Operating cash flowPCSA Free cash flowPCSA Capital expendituresPCSA Return on equityPCSA Stock buybacksPCSA Dividends paidPCSA Total assetsPCSA Total liabilitiesPCSA Shareholders’ equityPCSA overview →